Elusys Therapeutics

25 Riverside Dr
Pine Brook, NJ

Elusys Therapeutics News

Elusys awarded $16 million to continue anthrax treatment development

Thursday, Oct 8, 2015 @ 8:24am by BioPrepWatch Reports

Elusys Therapeutics Inc. has been awarded a $16-million contract from the Biomedical Advanced Research and Development Authority (BARDA), the company announced on Tuesday.
Read More »

FDA grants approval for anthrax treatment

Monday, Jun 1, 2015 @ 2:48pm by BioPrepWatch Reports

The Food and Drug Administration has accepted a Biologics License Application (BLA) for review from Elusys Therapeutics Inc.'s potential treatment for anthrax, Anthim, the company announced Monday.
Read More »

Anthrax anti-toxin from Elusys shows promise in preliminary trials

Thursday, Feb 12, 2015 @ 3:58pm by BioPrepWatch Reports

Elusys Therapeutics announced on Thursday promising preclinical trial results for treatments against Anthrax infections during the American Society for Microbiology Biodefense and Emerging Diseases Research meeting.
Read More »

Elusys Therapeutics concludes study on anthrax antitoxin

Tuesday, Sep 23, 2014 @ 1:24pm by BioPrepWatch Reports

Elusys Therapeutics announced on Monday that it has completed a three-phase study on an antitoxin in development to treat anthrax.
Read More »